Stephen Mallett

1.7k total citations · 1 hit paper
22 papers, 1.0k citations indexed

About

Stephen Mallett is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Stephen Mallett has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 5 papers in Surgery. Recurrent topics in Stephen Mallett's work include Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (7 papers) and Eosinophilic Esophagitis (5 papers). Stephen Mallett is often cited by papers focused on Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (7 papers) and Eosinophilic Esophagitis (5 papers). Stephen Mallett collaborates with scholars based in United States, United Kingdom and Australia. Stephen Mallett's co-authors include Gerald J. Gleich, Amy D. Klion, Frank Moosig, Ulrich Specks, Judith C. Brown, Michael E. Wechsler, Praveen Akuthota, Carol A. Langford, María C. Cid and Peter A. Merkel and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Neurology.

In The Last Decade

Stephen Mallett

20 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

2017 589 citations Michael E. Wechsler, Praveen Akuthota et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Stephen Mallett

Since Specialization

Citations

This map shows the geographic impact of Stephen Mallett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Mallett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Mallett more than expected).

Fields of papers citing papers by Stephen Mallett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Mallett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Mallett. The network helps show where Stephen Mallett may publish in the future.

Co-authorship network of co-authors of Stephen Mallett

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Mallett. A scholar is included among the top collaborators of Stephen Mallett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Mallett. Stephen Mallett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Measurement and Modeling of Peripherally Administered Anti-CGRP Monoclonal Antibody in CSF and Brain of Healthy Volunteers (S22.006) 2024 ·Neurology ·(unknown), (unknown), Edward T. Hellriegel, (unknown), (unknown), (unknown), Hang Zeng, Xiaofeng Lu, (unknown), Thelma S. Angeles, (unknown), James Wang, Stephen Mallett, Steve Barash, Laura Rabinovich‐Guilatt, Peter J. Goadsby, (unknown)	2
2	Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations 2023 ·Clinical Kidney Journal ·(unknown), Renato D. Lópes, Csaba P. Kövesdy, Aleix Cases, Stephen Mallett, Nick Ballew, (unknown), (unknown), Rajeev Ayyagari, (unknown), Kirsten L. Johansen, Alex J. Sutton, Indranil Dasgupta	4
3	Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials 2022 ·Nephrology Dialysis Transplantation ·Ajay Singh, Finnian R. Mc Causland, Brian Claggett, Christoph Wanner, Andrzej Więcek, Michael B. Atkins, Kevin Carroll, Vlado Perkovic, John J.V. McMurray, Janet Wittes, Steven Snapinn, (unknown), Amy M. Meadowcroft, (unknown), Tara DiMino, Stephen Mallett, Alexander R. Cobitz, Scott D. Solomon	8
4	Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Prespecified Analysis of the ASCEND-D Trial 2022 ·Journal of the American Society of Nephrology ·Indranil Dasgupta, Stephen Mallett, (unknown), Anjali Acharya, (unknown), Ricardo Correa-Rotter, Shruti Gupta, Vijay Kher, (unknown), Anjay Rastogi, Mai Ots-Rosenberg, Brian Rayner, Muh Geot Wong, Ajay Singh	0
5	Hemoglobin Stability in the ASCEND-D and -ND Trials 2022 ·Journal of the American Society of Nephrology ·Vivekanand Jha, Kirsten L. Johansen, Pablo E. Pérgola, Daniel W. Coyne, Katie St. Ledger, Stephen Mallett, (unknown), (unknown), Ajay Singh	0
6	Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials 2022 ·European Heart Journal ·Ajay Singh, Anjali Acharya, (unknown), Renato D. Lópes, Finnian R. McCausland, Laura Mulloy, Vlado Perkovic, (unknown), Sushrut S. Waikar, C. Wanner, Muh Geot Wong, Alexander R. Cobitz, Stephen Mallett, (unknown), John J.V. McMurray	4
7	Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials 2021 ·Respiratory Research ·Catherine Lemière, Camille Taillé, (unknown), Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric Bradford, Steven W. Yancey, Mark C. Liu	24
8	Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis 2021 ·The Journal of Allergy and Clinical Immunology In Practice ·Njira Lugogo, Mark C. Liu, Ian Pavord, Patrick Mitchell, Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric Bradford, Steven W. Yancey, Elisabeth H. Bel	1
9	Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes 2021 ·Journal of Asthma and Allergy ·Charlene M. Prazma, Marco Idzko, John Aubrey Douglass, Arnaud Bourdin, Stephen Mallett, Frank C. Albers, Steven W. Yancey	12
10	Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions 2021 ·Respiratory Research ·Peter G. Gibson, Charlene M. Prazma, Geoffrey Chupp, Eric Bradford, Mark Forshag, Stephen Mallett, Steve Yancey, Steven G. Smith, Elisabeth H. Bel	36
11	Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease 2019 ·Journal of Allergy and Clinical Immunology ·Charlene M. Prazma, Frank C. Albers, Stephen Mallett, (unknown), Steven W. Yancey	7
12	Association of depressive symptoms with health status and markers of uncontrolled severe asthma 2019 ·Allergy and Asthma Proceedings ·Sandhya Khurana, Jeffrey M. Lyness, Stephen Mallett, Linda Nelsen, Charlene M. Prazma, Frank C. Albers, Mark Forshag, Jean‐Pierre Llanos, Steven W. Yancey, Héctor Ortega	5
13	BASELINE PERCENT PREDICTED FEV1 DOES NOT PREDICT A RESPONSE TO MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA: META-ANALYSIS FROM TWO PHASE 3 TRIALS 2019 ·CHEST Journal ·Jared Silver, Andrew Menzies‐Gow, Steven G. Smith, Stephen Mallett, Eric Bradford, Steven W. Yancey, Frank C. Albers	4
14	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis 2018 ·Journal of Allergy and Clinical Immunology ·Jonathan Steinfeld, Eric Bradford, Judith C. Brown, Stephen Mallett, Steven W. Yancey, Praveen Akuthota, María C. Cid, Gerald J. Gleich, David Jayne, Paneez Khoury, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, Peter F. Weller, Michael E. Wechsler	87
15	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis breakdown → 2017 ·New England Journal of Medicine ·Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, María C. Cid, Raashid Luqmani, Judith C. Brown, Stephen Mallett, Richard Philipson, Steve Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich	589
16	Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials 2016 ·PLoS ONE ·Emilia Quattrocchi, Mikkel Østergaard, Peter C. Taylor, Ronald van Vollenhoven, Myron Chu, Stephen Mallett, (unknown), Regina Kurrasch	18
17	Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma 2016 ·Pulmonary Pharmacology & Therapeutics ·Robert Chan, Ana R. Sousa, Stephen Mallett, (unknown), (unknown), Maggie Tabberer, Rashmi Mehta	1
18	A Randomized, Crossover Study to Investigate the Pharmacokinetics and Safety of Inhaled Fluticasone Furoate and Umeclidinium, Administered Separately and in Combination via Dry Powder Inhaler in Healthy Adult Volunteers 2015 ·Advances in Therapy ·Shuying Yang, (unknown), Stephen Mallett, (unknown), (unknown), Steven Pascoe	6
19	Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes 2012 ·Journal of Allergy and Clinical Immunology ·Florence Roufosse, Jean‐Emmanuel Kahn, Gerald J. Gleich, Lawrence B. Schwartz, (unknown), Lanny J. Rosenwasser, Judah A. Denburg, Johannes Ring, Marc E. Rothenberg, Javed Sheikh, (unknown), Stephen Mallett, (unknown), Héctor Ortega, Amy D. Klion	136
20	Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial 2011 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Emilia Quattrocchi, Stephen Mallett, Regina Kurrasch, Jørgen Holm Petersen, David J. Chang	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact